🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Cutaneous Sarcoma

Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors NCT04068155NA2 sites📍 Grenoble📍 Lyon Alpha Tau Medical LTD. · Tests: DaRT- Diffusing Alpha-emitters Radiation Therapy Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers NCT06967961NA1 site📍 Toulouse Institut Claudius Regaud · Tests: For each enrolled patient, the sample described below will be collected as specific intervention intended for research … ACTengine® IMA203 Combined With mRNA-4203 NCT06946225Phase 14 sites📍 San Francisco📍 Boston📍 New York Immatics US, Inc. · Tests: IMA203, mRNA-4203 A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: MQ719, Pembrolizumab Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. NCT03889899NA1 site📍 Haifa Alpha Tau Medical LTD. · Tests: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors NCT05269381Phase 1, Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial NCT06580002Phase 21 site📍 Orange University of California, Irvine · Tests: Riluzole, Placebo Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia NCT04534127NA1 site📍 Jerusalem Alpha Tau Medical LTD. · Tests: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) NCT05824975Phase 1, Phase 211 sites📍 Scottsdale📍 Jacksonville📍 Rochester GI Innovation, Inc. · Tests: GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma NCT07007273Phase 23 sites📍 Tampa📍 Columbus📍 Houston H. Lee Moffitt Cancer Center and Research Institute · Tests: Pembrolizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy